Oral iron with antimalarial prophylaxis vs placebo or no treatment
Oral iron with antimalarial prophylaxis leads to lower clinical malaria compared with placebo or no treatment (high certainty).
- RR 0.54 [0.43, 0.67]728 participantsHigh
Oral iron with antimalarial prophylaxis leads to lower clinical malaria compared with placebo or no treatment (high certainty).
(Maternal outcomes) Any supplements containing iron may leads to lower maternal iron deficiency at term (as defined by as defined by… compared with same supplements without iron or no treatment/placebo (no iron or… (low certainty).
(Maternal outcomes) Any supplements containing iron and folic acid may leads to lower maternal iron deficiency at term (as defined by trialists, based on… compared with same supplements without iron nor folic acid (no iron nor folic acid… (low certainty).
Intravenous iron showed no clear difference in maternal mortality Clinical assessment compared with oral iron (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether intravenous iron changes infections Clinical assessment compared with oral iron (very low certainty).
It is very uncertain whether intravenous iron changes constipation Reported by the women compared with oral iron (very low certainty).
It is very uncertain whether intravenous iron changes all gastrointestinal symptoms Reported by the women compared with oral iron (very low certainty).
Intravenous iron showed no clear difference in anaphylaxis or evidence of hypersensitivity Clinical assessment compared with oral iron (low certainty).
It is very uncertain whether any intermittent iron regimen (with or without other vitamins and… changes maternal iron‐deficiency anaemia at term (Hb less than 110 g/L and… compared with daily regimen (with same vitamins and minerals)‐maternal outcomes (very low certainty).
IV iron sucrose showed no clear difference in number of responders ‐ active or inactive disease (6 weeks) compared with oral iron sulphate (low certainty).
It is very uncertain whether IV iron sucrose changes serious adverse events ‐ mild to moderate disease (20 weeks) compared with oral iron sulphate (very low certainty).
It is very uncertain whether parenteral iron changes mortality compared with oral iron (very low certainty).
It is very uncertain whether parenteral iron changes proportion requiring blood transfusion compared with oral iron (very low certainty).
It is very uncertain whether parenteral iron changes serious adverse events compared with oral iron (very low certainty).